These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33807238)

  • 21. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
    Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
    Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.
    Bartholdi D; Roelfsema JH; Papadia F; Breuning MH; Niedrist D; Hennekam RC; Schinzel A; Peters DJ
    J Med Genet; 2007 May; 44(5):327-33. PubMed ID: 17220215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant forms of histone acetyltransferases in human disease.
    Van Beekum O; Kalkhoven E
    Subcell Biochem; 2007; 41():233-62. PubMed ID: 17484131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration.
    Schoof M; Launspach M; Holdhof D; Nguyen L; Engel V; Filser S; Peters F; Immenschuh J; Hellwig M; Niesen J; Mall V; Ertl-Wagner B; Hagel C; Spohn M; Lutz B; Sedlacik J; Indenbirken D; Merk DJ; Schüller U
    Acta Neuropathol Commun; 2019 Dec; 7(1):199. PubMed ID: 31806049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients.
    Pérez-Grijalba V; García-Oguiza A; López M; Armstrong J; García-Miñaur S; Mesa-Latorre JM; O'Callaghan M; Pineda Marfa M; Ramos-Arroyo MA; Santos-Simarro F; Seidel V; Domínguez-Garrido E
    Mol Genet Genomic Med; 2019 Nov; 7(11):e972. PubMed ID: 31566936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EP300-related Rubinstein-Taybi syndrome: Highlighted rare phenotypic findings and a genotype-phenotype meta-analysis of 74 patients.
    Cohen JL; Schrier Vergano SA; Mazzola S; Strong A; Keena B; McDougall C; Ritter A; Li D; Bedoukian EC; Burke LW; Hoffman A; Zurcher V; Krantz ID; Izumi K; Bhoj E; Zackai EH; Deardorff MA
    Am J Med Genet A; 2020 Dec; 182(12):2926-2938. PubMed ID: 33043588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further delineation of an entity caused by CREBBP and EP300 mutations but not resembling Rubinstein-Taybi syndrome.
    Menke LA; ; Gardeitchik T; Hammond P; Heimdal KR; Houge G; Hufnagel SB; Ji J; Johansson S; Kant SG; Kinning E; Leon EL; Newbury-Ecob R; Paolacci S; Pfundt R; Ragge NK; Rinne T; Ruivenkamp C; Saitta SC; Sun Y; Tartaglia M; Terhal PA; van Essen AJ; Vigeland MD; Xiao B; Hennekam RC
    Am J Med Genet A; 2018 Apr; 176(4):862-876. PubMed ID: 29460469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease.
    Mathewson ND; Jenq R; Mathew AV; Koenigsknecht M; Hanash A; Toubai T; Oravecz-Wilson K; Wu SR; Sun Y; Rossi C; Fujiwara H; Byun J; Shono Y; Lindemans C; Calafiore M; Schmidt TM; Honda K; Young VB; Pennathur S; van den Brink M; Reddy P
    Nat Immunol; 2016 May; 17(5):505-513. PubMed ID: 26998764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rubinstein-Taybi syndrome in diverse populations.
    Tekendo-Ngongang C; Owosela B; Fleischer N; Addissie YA; Malonga B; Badoe E; Gupta N; Moresco A; Huckstadt V; Ashaat EA; Hussen DF; Luk HM; Lo IFM; Hon-Yin Chung B; Fung JLF; Moretti-Ferreira D; Batista LC; Lotz-Esquivel S; Saborio-Rocafort M; Badilla-Porras R; Penon Portmann M; Jones KL; Abdul-Rahman OA; Uwineza A; Prijoles EJ; Ifeorah IK; Llamos Paneque A; Sirisena ND; Dowsett L; Lee S; Cappuccio G; Kitchin CS; Diaz-Kuan A; Thong MK; Obregon MG; Mutesa L; Dissanayake VHW; El Ruby MO; Brunetti-Pierri N; Ekure EN; Stevenson RE; Muenke M; Kruszka P
    Am J Med Genet A; 2020 Dec; 182(12):2939-2950. PubMed ID: 32985117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p300/CBP and cancer.
    Iyer NG; Ozdag H; Caldas C
    Oncogene; 2004 May; 23(24):4225-31. PubMed ID: 15156177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype.
    Menke LA; van Belzen MJ; Alders M; Cristofoli F; ; Ehmke N; Fergelot P; Foster A; Gerkes EH; Hoffer MJ; Horn D; Kant SG; Lacombe D; Leon E; Maas SM; Melis D; Muto V; Park SM; Peeters H; Peters DJ; Pfundt R; van Ravenswaaij-Arts CM; Tartaglia M; Hennekam RC
    Am J Med Genet A; 2016 Oct; 170(10):2681-93. PubMed ID: 27311832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microbiota-derived butyrate limits the autoimmune response by promoting the differentiation of follicular regulatory T cells.
    Takahashi D; Hoshina N; Kabumoto Y; Maeda Y; Suzuki A; Tanabe H; Isobe J; Yamada T; Muroi K; Yanagisawa Y; Nakamura A; Fujimura Y; Saeki A; Ueda M; Matsumoto R; Asaoka H; Clarke JM; Harada Y; Umemoto E; Komatsu N; Okada T; Takayanagi H; Takeda K; Tomura M; Hase K
    EBioMedicine; 2020 Aug; 58():102913. PubMed ID: 32711255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction of a de novo Creb-binding protein gene mutation in sperm to produce a Rubinstein-Taybi syndrome model using inbred C57BL/6 mice.
    Takagi T; Higashi Y; Asai M; Ishii S
    Brain Res; 2020 Dec; 1749():147140. PubMed ID: 33022214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration.
    Alarcón JM; Malleret G; Touzani K; Vronskaya S; Ishii S; Kandel ER; Barco A
    Neuron; 2004 Jun; 42(6):947-59. PubMed ID: 15207239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypothesis: butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation.
    Corfe BM
    Mol Biosyst; 2012 Jun; 8(6):1609-12. PubMed ID: 22446977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.
    Al-Qattan MM; Jarman A; Rafique A; Al-Hassnan ZN; Al-Qattan HM
    BMC Med Genet; 2019 Jan; 20(1):12. PubMed ID: 30635043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptome Analysis of iPSC-Derived Neurons from Rubinstein-Taybi Patients Reveals Deficits in Neuronal Differentiation.
    Calzari L; Barcella M; Alari V; Braga D; Muñoz-Viana R; Barlassina C; Finelli P; Gervasini C; Barco A; Russo S; Larizza L
    Mol Neurobiol; 2020 Sep; 57(9):3685-3701. PubMed ID: 32562237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rubinstein-Taybi syndrome: clinical features, genetic basis, diagnosis, and management.
    Milani D; Manzoni FM; Pezzani L; Ajmone P; Gervasini C; Menni F; Esposito S
    Ital J Pediatr; 2015 Jan; 41():4. PubMed ID: 25599811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome.
    Murata T; Kurokawa R; Krones A; Tatsumi K; Ishii M; Taki T; Masuno M; Ohashi H; Yanagisawa M; Rosenfeld MG; Glass CK; Hayashi Y
    Hum Mol Genet; 2001 May; 10(10):1071-6. PubMed ID: 11331617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CBP histone acetyltransferase activity regulates embryonic neural differentiation in the normal and Rubinstein-Taybi syndrome brain.
    Wang J; Weaver IC; Gauthier-Fisher A; Wang H; He L; Yeomans J; Wondisford F; Kaplan DR; Miller FD
    Dev Cell; 2010 Jan; 18(1):114-25. PubMed ID: 20152182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.